Interleukin-6 is believed to play a pivotal role in the cytokine release syndrome and systemic inflammation and coagulation in severe COVID-19 patients and IL-6 receptor blockade by immune-modulatory agent; i.e., tocilizumab has gained popularity in the treatment of COVID-19 [14]. This evidence concerns the gene IL6 and COVID-19.